Array Biopharma Inc (NASDAQ:ARRY) has entered into a clinical study collaboration deal with Pfizer Inc (NYSE:PFE) to investigate the efficacy and safety of numerous unique anti-cancer combinations, including company’s binimetinib, with Pfizer’s talazoparib, and avelumab. The firms have finalized this deal to assess the prospective advantages of combining molecularly targeted therapeutics and the body’s distinctive cancer-fighting abilities utilizing immunotherapy.
Ron Squarer, the CEO of Array Biopharma, reported that the company is thrilled to report this deal with Pfizer, a renowned international pioneer in Oncology therapeutics. These unique approaches combining immunotherapy and targeted therapy showcases remarkable potential to help people fighting cancer in several indications, with a preliminary focus on pancreatic and lung cancer.
Chris Boshoff, M.D., Ph.D. from Pfizer, expressed that preclinical study indicate that combining binimetinib with talazoparib and an immune checkpoint inhibitor could be an ideal combination to assess in the clinic. They are looking forward to starting the clinical trials with Array Biopharma to evaluate anti-tumor activity across different unique combination strategies, including doublet as well as triplet approaches.
As per the terms of the deal, Pfizer and Array will associate on a Phase Ib clinical study to evaluate a series of unique combinations, investigating the efficacy and safety of the combination of binimetinib, talazoparib and avelumab across different tumor types.
A multi-arm clinical study is projected to establish recommended doses of various regimens combining the medicines. Primarily the focus will be in pancreatic cancer and non-small cell lung cancer, and additional cases will be evaluated at a later stage. The trial is expected to commence by the third quarter of 2018. Report from this trial will be used to decide optimal approaches to further clinical advancement of these combinations. The study will be funded and sponsored by Pfizer, with Array offering binimetinib supply.
In the last trading session, the stock price of Array Biopharma gained more than 1% to close the day at $12.51.